Form 4: Verve Therapeutics Completes Eli Lilly Acquisition; Chief Technical Officer's Equity Converted

Verve Therapeutics, Inc. has completed its merger with Eli Lilly and Company, resulting in the conversion of all outstanding common stock, stock options, and restricted stock units into cash and contingent value rights.

Summary

• Verve Therapeutics, Inc. has been acquired by Eli Lilly and Company through its indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, with the merger effective as of July 25, 2025.
• As part of the acquisition, tendering stockholders received $10.50 per share in cash (Cash Consideration) and one non-tradable contingent value right (CVR) per share, representing a contractual right to receive up to an additional $3.00 per CVR upon the achievement of a specified milestone.
• Following the tender offer, Ridgeway Acquisition Corporation merged with and into Verve Therapeutics, Inc., making Verve a wholly owned subsidiary of Eli Lilly and Company.
• Jason Politi, Chief Technical Operations Officer, disposed of 16,405 shares of common stock, which included 2,179 shares acquired in 2025 under the Employee Stock Purchase Plan.
• Stock options with an exercise price less than the Cash Consideration ($10.50), totaling 225,000 options at $6.01 and 118,796 options at $8.24, were cancelled; holders received cash equal to the difference between the Cash Consideration and the exercise price, multiplied by the number of shares, plus one CVR per share.
• Unvested Restricted Stock Units (RSUs), totaling 40,000, 6,630, and 16,500 units, were cancelled; holders received cash equal to the Cash Consideration multiplied by the number of shares, plus one CVR per RSU.
• Stock options with an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (e.g., 25,000 options at $11.57 and 90,000 options at $12.75) were cancelled; holders are entitled to receive a cash amount based on the CVR payment, provided it represents the excess of the sum of the Cash Consideration and Milestone Payment over the exercise price.

Sentiment

Score: 8

Explanation: The sentiment is positive as the filing confirms the successful completion of an acquisition, providing shareholders with a defined cash value and potential upside through CVRs, indicating a favorable outcome for the acquired company's investors.

Positives

• Shareholders received an immediate cash payment of $10.50 per share, providing liquidity.
• Shareholders and equity holders (stock options, RSUs) have the potential to receive an additional $3.00 per CVR upon the achievement of a specified milestone, offering further upside.
• The acquisition provides a clear exit strategy and valuation for Verve Therapeutics shareholders.

Negatives

• Verve Therapeutics, Inc. is no longer an independent publicly traded company, removing its stock from public exchanges.
• Shareholders lose direct equity participation in the future growth and innovation of Verve Therapeutics beyond the contingent value right.

Risks

• The contingent payment of up to $3.00 per CVR is not guaranteed and is dependent on the achievement of a specific, undisclosed milestone relating to Verve's business.

Future Outlook

The filing primarily details a completed transaction. The only forward-looking aspect is the potential future payment of the contingent value rights (CVRs) upon the achievement of a specified milestone, which is not detailed in terms of timeline or specific conditions beyond its existence.

Industry Context

This acquisition exemplifies a common trend in the biotechnology and pharmaceutical sectors where larger, established companies like Eli Lilly acquire smaller, innovative biotech firms like Verve Therapeutics to expand their pipeline, gain access to novel technologies, or eliminate competition. Such mergers often provide a significant return for the acquired company's shareholders and integrate promising assets into a larger development framework.

Comparison to Industry Standards

• The filing does not provide sufficient information, such as the premium paid over the pre-announcement share price or specific financial metrics of Verve Therapeutics, to conduct a detailed comparison to industry benchmarks for biotech acquisitions. Typical biotech acquisitions often involve premiums ranging from 30% to over 100% depending on the stage of development, market potential, and competitive landscape of the acquired assets.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration and contingent value rights for their shares, providing a defined return on investment.
• Employees (including reporting person): Equity holdings (stock options, RSUs) were converted into cash and CVRs, providing liquidity and potential future payments based on the merger terms.
• Company (Verve Therapeutics): Ceases to be an independent public entity and operates as a subsidiary of Eli Lilly, potentially benefiting from greater resources and integration into a larger pharmaceutical company's operations.

Next Steps

• Achievement of the specified milestone for the contingent value rights (CVRs) to trigger the potential additional payment of up to $3.00 per CVR.

Key Dates

Keywords

Verve Therapeutics, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Stock Option, Restricted Stock Units, Contingent Value Right, Biotechnology, Pharmaceutical, VERV